| HOME | |
| Patient Resources | The Program of Care |
| Study Details | The Evaluation Process |
| Staff | Waiting for a Transplant |
| Links | The Transplant Procedure |
| After the Transplant | |
Islet Cell Transplantation
The Evaluation Process
Provided that patients meet inclusion criteria for the study, they will receive a packet of information and a list of requested diagnostic tests in the mail. These diagnostic tests will include at least the following (based on your medical history):
- cardiac stress test
- chest X-ray
- electrocardiogram (EKG)
- dental and eye exams
- mammogram
- pap smear test
- urine and blood tests.
To continue with the evaluation process, the patient will complete these tests and return the results (with other information requested in the packet) to the study coordinator. Many of these tests can be performed by the patient’s own doctor. This packet will also contain a draft consent form that will explain, in detail, the procedure, the potential benefits, the risks, and the costs associated with islet cell transplantation.
If, based upon the medical information submitted, the patient remains a candidate, an appointment will be made for a formal overnight evaluation visit to the General Clinical Research Center (GCRC) at the University of Virginia Health System.
The evaluation will consist of a review of the consent form and study requirements. Once the consent form is signed, the patient will be seen by the study coordinator, a study physician, a social worker and an endocrinologist. Various medical diagnostic tests will be performed. These will include (but may not be limited to): an oral glucose tolerance test (which will require IV insulin); collection of glucose data through a continuous 72-hour glucose monitor; an updated chest X-ray and EKG (if needed); liver ultrasound; blood and urine tests.
Financial Matters
Due to the fact that islet cell transplantation is being conducted as part of a federally-supported study, the overnight evaluation, the inpatient transplant stay and the islet cells used during the transplant procedure are paid for by the study grant. The cost of the anti-rejection drugs following the transplant, however, will be the patient's responsibility.